Sildenafil
Treatment for Pulmonary Arterial Hypertension
Typical Dosage: 20mg three times daily
Effectiveness
80%
Safety Score
60%
Clinical Trials
125
Participants
12K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
20mg three times daily
Time to Effect
Weeks to months
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
5(Treat 5 patients to see 1 additional successful outcome)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$2,000
Monitoring:$4,500
Side Effect Mgmt:$300
Total Annual:$6,800
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTQALYs Gained
0.2
Outcome-Based Costs
Cost per Responder
$17,000
Cost per Remission
$85,000
Sildenafil Outcomes
for Pulmonary Arterial Hypertension
Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+40%
Remission Rate
+8%
Common Side Effects
Headache
+50%
Flushing
+25%
Dyspepsia
+18%
Nasal Congestion
+12%
Visual Disturbances
+10%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
11 completed trials for Sildenafil in Pulmonary Arterial Hypertension
Evaluate The Clinical Effectiveness, Safety And Tolerability Of Sildenafil Used In Doses ≥20mg TID For The Treatment Of Pulmonary Arterial Hypertension
NCT01365585COMPLETED
227 participants
OBSERVATIONAL
Hanover, Germany +1 more
Started: Jul 1, 2011
Revatio Special Investigation for Long-term Use in Pediatric Patients
NCT03364244COMPLETED
1.02K participants
OBSERVATIONAL
Tokyo, Japan
Started: Nov 30, 2017
A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children
NCT00159874COMPLETEDPHASE3
234 participants
INTERVENTIONAL
Palo Alto, United States +38 more
Started: Jan 1, 2004
Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension
NCT01642407COMPLETEDPHASE4
6 participants
INTERVENTIONAL
Sagamihara, Japan +4 more
Started: Aug 24, 2012
Responsiveness of Exercise Tests in Pulmonary Arterial Hypertension
NCT01391104COMPLETEDNA
22 participants
INTERVENTIONAL
Québec, Canada
Started: Apr 1, 2009
Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants
NCT01392469COMPLETEDPHASE3
21 participants
INTERVENTIONAL
Tampa, United States +10 more
Started: Apr 20, 2011
Combination Therapy in Pulmonary Arterial Hypertension
NCT00433329COMPLETEDPHASE4
100 participants
INTERVENTIONAL
Started: Mar 1, 2007
A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in Children With Pulmonary Arterial Hypertension.
NCT00159913COMPLETEDPHASE3
235 participants
INTERVENTIONAL
Palo Alto, United States +40 more
Started: Aug 1, 2003
Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Sildenafil
NCT04994860COMPLETEDPHASE1
20 participants
INTERVENTIONAL
Berlin, Germany
Started: Mar 22, 2018
Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)
NCT00617305COMPLETEDPHASE4
38 participants
INTERVENTIONAL
Mobile, United States +29 more
Started: Apr 1, 2008
Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
NCT00323297COMPLETEDPHASE4
105 participants
INTERVENTIONAL
Los Angeles, United States +29 more
Started: Sep 1, 2006
Showing 20 of 125 total trials